Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Frequently asked questions
What sector does Clarity Pharmaceuticals Ltd (CLRPF) operate in?
Clarity Pharmaceuticals Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Clarity Pharmaceuticals Ltd (CLRPF) current stock price?
As of the latest data, Clarity Pharmaceuticals Ltd stock price is $1.08, with a previous close of $1.11. Clarity Pharmaceuticals Ltd lost -$0.02 in the last trading session, representing a -1.99% loss.
What is Clarity Pharmaceuticals Ltd (CLRPF) current market capitalization?
Clarity Pharmaceuticals Ltd market cap is approximately 404.05 million.
What is Clarity Pharmaceuticals Ltd (CLRPF) Earnings Per Share (EPS)?
The trailing EPS is -$0.20.
Does Clarity Pharmaceuticals Ltd (CLRPF) pay dividends?
No. Clarity Pharmaceuticals Ltd does not pay a dividend.
What is Clarity Pharmaceuticals Ltd (CLRPF) beta (volatility) score?
Clarity Pharmaceuticals Ltd has a beta of 1.176, meaning its volatility is roughly in line with the market.